Cited by 218SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 29 of the 34 references it cites were found in a registry or an index, and 2 are not checked yet.

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Open access

Wang, Kai, Long, Quan-Xin, Deng, Hai-Jun, Hu, Jie, Gao, Qing-Zhu, Zhang, Gui-Ji, He, Chang-Long, Huang, Lu-Yi, Hu, Jie-Li, Chen, Juan, Tang, Ni, Huang, Ai-Long·2021·Clinical Infectious Diseases

DOI 10.1093/cid/ciaa1143PMC PMC7454328

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific neutralizing antibodies (NAbs) in patients with COVID-19. Methods: Blood samples (n = 173) were collected from 30 patients with COVID-19 over a 3-month period after symptom onset and analyzed for SARS-CoV-2–specific NAbs using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines. Results: SARS-CoV-2–specific NAb titers were low for the first 7–10 days after symptom onset and increased after 2–3 weeks. The median peak time for NAbs was 33 days (interquartile range [IQR], 24–59 days) after symptom onset. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR, 19.6–42.4%). NAb titers increased over time in parallel with the rise in immunoglobulin G (IgG) antibody levels, correlating well at week 3 (r = 0.41, P < .05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including stem cell factor (SCF), TNF-related apoptosis-inducing ligand (TRAIL), and macrophage colony-stimulating factor (M-CSF). Conclusions: These data provide useful information regarding dynamic changes in NAbs in patients with COVID-19 during the acute and convalescent phases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa1143

Cites

29 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Analysis of the plasma response to SARS-CoV-2 infection. A, Sera from 5 convalescent patients with COVID-19 neutralized the SARS-CoV-2 pseudovirus. A serum sample from a healthy individual served as the negative control. The assay was performed in triplicate, and the median percentage of neutralization is shown. B, SARS-CoV-2 NAb titers of 20 plasma samples from convalescent patients with COVID-19 and 10 plasma samples from healthy donors. C, NAbs against VSVG, SARS-CoV, and SARS-CoV-2 pseudovirus in the sera from 30 convalescent patients with COVID-19. Abbreviations: COVID-19, coronavirus disease 2019; F, female; ID50, 50% inhibitory dose; M, male; NAb, neutralizing antibody; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VSVG, vesicular stomatitis virus G.CC BY-NC-ND · PubMed Central

Figure 2. Dynamic changes in NAbs against SARS-CoV-2. A, Kinetics of SARS-CoV-2 NAb levels in 30 patients with COVID-19. B, Number of patients experiencing peak NAb levels during hospitalization or after discharge. Follow-up point 1 represents the follow-up study conducted on 2 April while follow-up point 2 represents the follow-up study conducted on 8 May 2020. C, Peak NAb levels in the patients. D, Comparison of peak NAb levels between patients with COVID-19 experiencing peak NAb levels during hospitalization and patients with COVID-19 experiencing peak NAb levels after discharge. Abbreviations: COVID-19, coronavirus disease 2019; F, female; ID50, 50% inhibitory dose; M, male; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.CC BY-NC-ND · PubMed Central

Figure 3. Decrease in NAb levels in patients with COVID-19. A, Comparison of NAb levels between the peak point and the follow-up time point 2. B, Percentage decrease in NAbs in patients with COVID-19. Abbreviations: COVID-19, coronavirus disease 2019; ID50, 50% inhibitory dose; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.CC BY-NC-ND · PubMed Central

Figure 4. Correlation between the dynamics of NAb and virus-specific IgG levels. A, Kinetics of NAb and IgG levels in 6 patients. Plasma samples were collected at different time points after symptom onset. B, A total of 152 serum samples were grouped by time of collection after symptom onset; correlations were analyzed between NAb levels and IgG levels in each group. C, Correlations between NAb levels and IgG levels from serum samples collected 3 weeks after symptom onset. Abbreviations: F, female; ID50, 50% inhibitory dose; IgG, immunoglobulin G; M, male; NAb, neutralizing antibody.CC BY-NC-ND · PubMed Central

Figure 5. A–C, Correlation between peak NAb levels and cytokines in sera. Serum samples with the highest NAb levels for all individuals were collected during hospitalization. Cytokine or levels were measured using the Bio-Plex Human Cytokine Screening Panel (48-Plex no. 12007283; Bio-Rad) on a Luminex 200 (Luminex Multiplexing Instrument, Merck Millipore), following the manufacturer’s instructions. Pearson’s correlation was used to analyze differences between NAb levels and cytokine levels. Abbreviations: ID50, 50% inhibitory dose; M-CSF, macrophage colony-stimulating factor; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCF, stem cell factor; TRAIL, tumor necrosis factor (TNF)–related apoptosis-inducing ligand.CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Self-citation
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citation
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,298
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,968
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes
Connor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc2241 · Cited by 963
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816 · cited 1×
“Recently, in a rhesus macaque model, SARS-CoV-2 infection evoked a robust protective immune response when the animals were re-exposed to SARS-CoV-2 at 1 month after the initial viral infection [25].”
Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Self-citation
COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives
Sun, J., He, W.-T., Wang, L., Lai, A. C.-K., Ji, X., Zhai, X., Li, G., Suchard, M. A., Tian, J., Zhou, J., et al. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.02.008 · Cited by 710
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Kinetics of viral load and antibody response in relation to COVID-19 severity
Wang, Y., Zhang, L., Sang, L., Feng, Y., Ruan, S., Zhong, B., Song, T., Alshukairi, A. N., Chen, R., Zhang, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138759 · Cited by 542
The potential danger of suboptimal antibody responses in COVID-19
Iwasaki, A., & Yang, Y.-X. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0321-6 · Cited by 510
Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study
Tang, F., Quan, Y., Xin, Z.-T., Wrammert, J., Ma, M.-J., Lv, H., Wang, T.-B., Yang, H., Richardus, J. H., Liu, W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903490 · Cited by 496
The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development
Dutta, N. K., Mazumdar, K., & Gordy, J. T. (2020) · Journal of Virology · doi:10.1128/jvi.00647-20 · Cited by 407
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience
Ko, J. H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Ys, K., Kim, Y., Park, J. K., Chung, C. R., Kang, E., et al. (2017) · Antiviral Therapy · doi:10.3851/imp3243 · Cited by 323
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
Ng, D., Goldgof, G. M., Shy, B. R., Levine, A. G., Balcerek, J., Bapat, S. P., Prostko, J. C., Rodgers, M. A., Coller, K. E., Pearce, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18468-8 · Cited by 182
Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients
Luchsinger, L. L., Ransegnola, B. P., Jin, D. K., Muecksch, F., Weisblum, Y., Bao, W., George, P. J., Rodriguez, M., Tricoche, N., Schmidt, F., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02005-20 · Cited by 180
Comparison of lentiviral vector titration methods
Geraerts, M., Willems, S., Baekelandt, V., Debyser, Z., & Gijsbers, R. (2006) · BMC Biotechnology · doi:10.1186/1472-6750-6-34 · Cited by 171
Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients
Yang, L., Peng, H., Zhu, Z.-L., Li, G., Huang, Z., Zhao, Z., Koup, R. A., Bailer, R. T., & Wu, C. Y. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.05.002 · Cited by 115
A serological survey on neutralizing antibody titer of SARS convalescent sera
Zhang, J.-S., Chen, J.-T., Liu, Y.-X., Zhang, Z.-S., Gao, H., Liu, Y., Wang, X., Ning, Y., Liu, Y.-F., Gao, Q., et al. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20431 · Cited by 93
Self-citation
Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels
Harvala, H., Robb, M. L., Watkins, N. A., Ijaz, S., Dicks, S., Patel, M., Supasa, P., Dejnirattisai, W., Liu, C., Mongkolsapaya, J., et al. (2020) · Transfusion Medicine · doi:10.1111/tme.12746 · Cited by 86
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay AreaPreprint
Ng, D. L., Goldgof, G. M., Shy, B. R., et al. (2020) · medRxiv · doi:10.1101/2020.05.19.20107482 · Cited by 85
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levelsPreprint
Harvala, H., Robb, M. L., Watkins, N. A., et al. (2020) · medRxiv · doi:10.1101/2020.05.20.20091694 · Cited by 43
Pseudotyping Viral Vectors With Emerging Virus Envelope Proteins
Steffen, I., & Simmons, G. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160119093948 · Cited by 32
Neutralizing antibody response in mild COVID-19
van der Heide, V. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0325-2 · Cited by 26

Research works printed but not linked: 1

Luchsinger, 2020, Serological analysis of New York City COVID19 convalescent plasma donors, medRxiv

Sorted by citations

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Viral targets for vaccines against COVID-19
Dai, L., & Gao, G. F. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,056
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., Hansen, L., Haile, A., Klebert, M. K., Pusic, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03647-4 · Cited by 532

See all 218

Authors: Wang, K., Long, Q.-X., Deng, H.-J., Hu, J., Gao, Q.-Z., Zhang, G.-J., He, C.-L., Huang, L.-Y., Hu, J.-L., Chen, J., Tang, N., & Huang, A.-L.
Affiliations: Second Affiliated Hospital of Chongqing Medical University (CN)
Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Corresponding author: Huang, Ai-Long
ORCID: Wang, Kai
Hu, Jie
Chen, Juan
Tang, Ni
Huang, Ai-Long
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2020-08-03
Volume: 73
Issue: 3
Pages: e531-e539
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1093/cid/ciaa1143
PMC: PMC7454328
OpenAlex: W3046309975
Cited by: 218
References: 34
Citations by year: 2026: 1 · 2025: 8 · 2024: 15 · 2023: 26 · 2022: 37 · 2021: 101 · 2020: 30
FWCI: 6.36
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Science and Technology Commission of Chongqing (cstc2020jscx-fyzx0053)
Chongqing Medical University (CQMUNCP0302, CQMUNCP0304)
Leading Talent Program of Chongqing Science and Technology Commission (CSTCCXLJRC201719)
Major National Science and Technology Program (2017ZX10202203)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, antibody kinetics, IgG, inflammatory cytokines, stem cell factor, TRAIL, macrophage colony-stimulating factor, convalescence
MeSH terms: COVID-19, SARS-CoV-2, Antibodies, Viral, Humans, Antibodies, Neutralizing, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks